Document is current
Any future updates will be listed below
-
Authors
Loipfinger, Stefan https://orcid.org/0000-0002-5571-0435
Grosholz, Matthias
Kumar, Santhosh https://orcid.org/0009-0002-9663-1896
Erbilir, Helin
Dyar, Kenneth Allen
Müller, Timo Dirk https://orcid.org/0000-0002-0624-9339
Grein, Stephan https://orcid.org/0000-0001-9524-6633
Rozman, Jan https://orcid.org/0000-0002-8035-8904
Klingenspor, Martin https://orcid.org/0000-0002-4502-6664
Meyer, Carola https://orcid.org/0000-0001-7959-1218
Lutter, Dominik https://orcid.org/0000-0002-8800-0683
- License Information
-
More Information
Article History
First Online: 24 June 2025
Competing interests
: T.D.M. holds stocks from Eli Lilly and receives research funding from Novo Nordisk. T.D.M. further received speaking fees within the past 3 years from Merck, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. All remaining authors declare no competing interests.
